Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

Gastroenterology

Volumn 151, Issue 1, 2016, Pages 130-139.e2

  Di Marco, Vito ^a   Calvaruso, Vincenza ^a   Ferraro, Donatella ^a   Bavetta, Maria Grazia ^a   Cabibbo, Giuseppe ^a   Conte, Elisabetta ^a   Cammà, Calogero ^a   Grimaudo, Stefania ^a   Pipitone, Rosaria Maria ^a   Simone, Fabio ^a   Peralta, Sergio ^a   Arini, Andrea ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bleeding; Esophagus; Long Term Outcome; Portal Pressure

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE ERADICATION; ESOPHAGUS VARICES; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTENTION TO TREAT ANALYSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; VIRAL CLEARANCE; VIROLOGY; AGED; COMPLICATION; DRUG EFFECTS; ESOPHAGEAL AND GASTRIC VARICES; FOLLOW UP; HEPACIVIRUS; HYPERTENSION, PORTAL; ITALY; PROPORTIONAL HAZARDS MODEL; SUSTAINED VIROLOGIC RESPONSE;

AGED; ANTIVIRAL AGENTS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HUMANS; HYPERTENSION, PORTAL; INTENTION TO TREAT ANALYSIS; INTERFERON-ALPHA; ITALY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SUSTAINED VIROLOGIC RESPONSE;

EID: 84990068819     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.03.036     Document Type: Article

References (42)

1. 1 D'Ambrosio, R., Aghemo, A., Rumi, M.G., et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56 (2012), 532–543.
2. 2 Rincon, D., Ripoll, C., Lo Iacono, O., et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101 (2006), 2269–2274.
3. 3 Bruno, S., Stroffolini, T., Colombo, M., et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 45 (2007), 579–587.
4. 4 Veldt, B.J., Heathcote, E.J., Wedemeyer, H., et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147 (2007), 677–684.
5. 5 Morgan, T.R., Ghany, M.G., Kim, H.Y., et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52 (2010), 833–844.
6. 6 van der Meer, A.J., Veldt, B.J., Feld, J.J., et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308 (2012), 2584–2593.
7. 7 Hill, A.M., Saleem, J., Healt, K.A., et al. Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. AASLD, 2014 Boston 7−11 November: Abstract 44.
8. 8 Garcia-Tsao, G., Friedman, S., Iredale, J., et al. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 51, 2010, 1445.
9. 9 Jepsen, P., Vilstrup, H., Andersen, P.K., The clinical course of cirrhosis: the importance of multi-state models and competing risks analysis. Hepatology 62 (2015), 292–302.
10. 10 D'Amico, G., Garcia-Tsao, G., Pagliaro, L., Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 44 (2006), 217–231.
11. 11 D'Amico, G., Pasta, L., Morabito, A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39 (2014), 1180–1193.
12. 12 Gomez, E.V., Rodriguez, Y.S., Bertot, L.C., et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol 58 (2013), 434–444.
13. 13 Hézode, C., Fontaine, H., Dorival, C., et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 147 (2014), 132–142.
14. 14 European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60 (2014), 392–420.
15. 15 Gane, E., Hepatitis C beware−the end is nigh. Lancet 384 (2014), 1557–1560.
16. 16 Di Marco, V., Almasio, P.L., Ferraro, D., et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 47 (2007), 484–491.
17. 17 Di Marco, V., Calvaruso, V., Grimaudo, S., et al. Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of peg-interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. J Viral Hepat 20 (2013), 113–121.
18. 18 Bruix, J., Sherman, M., Llovet, J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001), 421–430.
19. 19 Bruix, J., Sherman, M., American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
20. 20 de Franchis, R., Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 33 (2000), 846–852.
21. 21 North-Italian Endoscopic Club for the study and treatment of esophageal varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med 319 (1988), 983–989.
22. 22 de Franchis, R., Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 43 (2005), 167–176.
23. 23 de Franchis, R., Baveno V Faculty, Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53 (2010), 762–768.
24. 24 Martin, P., Di Martini, A., Feng, S., et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 59 (2014), 1144–1165.
25. 25 Asselah, T., Bruno, S., Craxi, A., HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?. J Hepatol 6 (2014), 11430–11433.
26. 26 Innes, H., Goldberg, D., Dillon, J., et al. Strategies for the treatment of hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. Gut 64 (2015), 1800–1809.
27. 27 Merli, M., Nicolini, G., Angeloni, S., et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 38 (2003), 266–272.
28. 28 Groszmann, R.J., Garcia-Tsao, G., Bosch, J., et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 353 (2005), 2254–2261.
29. 29 Fontana, R.J., Sanyal, A.J., Ghany, M.G., et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 138 (2010), 2321–2331.
30. 30 Bruno, S., Crosignani, A., Facciotto, C., et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51 (2010), 2069–2076.
31. 31 Zoli, M., Merkel, C., Magalotti, D., et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastroenterol 95 (2000), 503–508.
32. 32 Merkel, C., Marin, R., Angeli, P., et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology 127 (2004), 476–484.
33. 33 Colecchia, A., Montrone, L., Scaioli, E., et al. Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis. Gastroenterology 143 (2012), 646–654.
34. 34 Calvaruso, V., Bronte, F., Conte, E., et al. Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis. J Viral Hepat 20 (2013), 867–874.
35. 35 Colecchia, A., Colli, A., Casazza, G., et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol 60 (2014), 1158–1164.
36. 36 Sangiovanni, A., Prati, G.M., Fasani, P., et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 43 (2006), 1303–1310.
37. 37 Huang, C.F., Yeh, M.L., Tsai, P.C., et al. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. J Hepatol 61 (2014), 67–74.
38. 38 Veldt, B.J., Chen, W., Heathcote, E.J., et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 47 (2008), 1856–1862.
39. 39 Arase, Y., Kobayashi, M., Suzuki, F., et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57 (2013), 964–973.
40. 40 Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
41. 41 Kottilil, S., Wright, M., Polis, M.A., et al. Treatment of hepatitis C virus infection: is it time for the internist to take the reins?. Ann Intern Med 161 (2014), 443–444.
42. 42 Deuffic-Burban, S., Deltenre, P., Buti, M., et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 143 (2012), 974–985.